Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026)

Sagimet Biosciences' Operating Expenses history runs 5 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 41.04% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $48.7 million (down 25.65% YoY), while the FY2025 annual figure was $56.9 million, up 4.47% from the prior year.
• Operating Expenses for Q1 2026 stood at $11.7 million, up from $10.8 million in the prior quarter.
• The five-year high for Operating Expenses was $19.9 million in Q1 2025, with the low at $6.8 million in Q1 2023.
• The 5-year median for Operating Expenses is $10.0 million (2023), against an average of $11.1 million.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 126.56% in 2025, then sank 41.04% in 2026.
• Sagimet Biosciences' Operating Expenses stood at $7.4 million in 2022, then advanced by 28.13% to $9.5 million in 2023, then jumped by 92.21% to $18.2 million in 2024, then plunged by 40.84% to $10.8 million in 2025, then rose by 8.81% to $11.7 million in 2026.
• Business Quant data shows SGMT's Operating Expenses at $11.7 million in Q1 2026, $10.8 million in Q4 2025, and $14.3 million in Q3 2025.